Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...

Johnson & Johnson shares are down 3% Wednesday on safety concerns that could dim sales prospects for a new heart device, ...

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...

Johnson & Johnson closed $26.58 below its 52-week high ($168.85), which the company reached on September 4th.

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson (JNJ) closed at $146.18 in the latest trading session, marking a +1.75% move from the prior day. The stock outpaced the S&P 500's daily loss of 1.11%. Elsewhere, the Dow saw a ...

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson (NYSE:JNJ – Get Free Report) was the target of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 17,570,000 ...

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow ...